Cytokinetics, Incorporated (Nasdaq: CYTK) has presented a broad package of new clinical data for MYQORZO at the European Society of Cardiology Heart Failure 2026 Congress. The presentations reinforced the clinical profile of
More
RayzeBio, a Bristol Myers Squibb company, plans to invest more than $173 million in central Indiana operations and build a major new manufacturing facility. The company will establish an approximately 450,000-square-foot facility
More
Roivant Sciences (ROIV) and its partner Priovant Therapeutics have secured FDA approval for Lisraya, a first-in-class oral treatment for the rare autoimmune disease dermatomyositis. The U.S. Food and Drug Administration approved Lisraya,
More
Gilead Sciences has secured regulatory approval from the US Food and Drug Administration for Bixlenvo, a new once-daily single-tablet HIV treatment combining two established compounds. The pill pairs bictegravir, the active backbone
More
Revolution Medicines (RVMD) is pushing forward with the commercial launch of daraxonrasib, branded as Rasonque, following a landmark approval from the US Food and Drug Administration. The drug represents a historic milestone
More
The Trump administration is preparing to announce fresh drug-pricing agreements with several midsized biotech companies as part of its most favoured nation pricing push. The companies involved will agree to provide discounts
More
AbbVie (ABBV) has announced 34 students living with chronic inflammatory conditions will receive its 2026 Immunology Scholarship as the programme marks its tenth year. Recipients span three key therapeutic areas, including dermatology,
More
Baxter International Inc. (NYSE: BAX) has initiated voluntary recalls of two injectable products after particulate matter contamination was identified in both solutions. The first recall involves two lots of 0.9% Sodium Chloride
More
Six months after its February 2026 launch, the White House’s TrumpRx platform has grown rapidly but continues to face scepticism from managed care professionals over genuine savings. The initiative launched with approximately
More
Akeso has announced a major clinical breakthrough, with its cancer drug ivonescimab meeting the primary endpoint of overall survival in a late-stage biliary tract cancer trial. The positive result comes from a
More